Pavol: What pieces of healthcare-related legislation might get done by the end of 2018 (specifically, looking at the American Innovation Act)? Where do you see President Trump’s latest drug pricing proposal going? Is it feasible?
Flood: In the 115th Congress, the House dealt with the American Innovation Act, but we’re not sure if there are enough votes in the Senate. Republicans in the House will want it to pass, but the Senate will not get the required 60 votes for it without support from Democrats, which appears unlikely.
Trump’s latest drug pricing proposal – the International Pricing Index model – would base Medicare Part B drug prices on other countries’ costs. Although not feasible in its current form, the Administration is dedicated to moving the concept forward. The proposed model doesn’t require Congressional approval, but pushback from lawmakers could lead to the Administration altering the proposal or scrapping it altogether.
There are other proposals from the President’s drug pricing plan that we expect to see movement on next year, some of which do require Congressional approval. There is also bipartisan agreement around improving transparency and bringing costs down.
Douglas: Cost is a big concern, and drug pricing has long been pursued by Congress. The administration responded to that with the President’s drug pricing blueprint.